Allergy and Immunology, Allergy · Dover, DE
NPI
1134181613
Since 2006
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
103 Wolf Creek Blvd Ste 1
Dover, DE, 19901
Phone (302) 734-4434
Groups this clinician bills Medicare through
Medicare paid, 2024
$87K
8,222 services
Medicare patients, 2024
416
Average age 71
Drug cost, 2024
$1.4M
3,950 prescriptions
Company payments, 2025
$775
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shankar Lakhani was code 95004 (test - miscellaneous), 4,150 times for 58 patients. In total Shankar Lakhani billed 8,222 services in 17 codes, and Medicare paid $87K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 4,150 | 58 | $2.71 | $11K |
| 95165 Treatment - Miscellaneous | Office | 2,000 | 64 | $10.43 | $21K |
| 95117 Treatment - Miscellaneous | Office | 1,061 | 66 | $8.34 | $8,849 |
| 94010 Pulmonary Function Testing | Office | 330 | 289 | $18.75 | $6,189 |
| 99213 Office E&M - Established | Office | 207 | 191 | $56.06 | $12K |
| 99214 Office E&M - Established | Office | 192 | 177 | $90.09 | $17K |
| 99204 Office E&M - New | Office | 47 | 47 | $118.70 | $5,579 |
| 94060 Pulmonary Function Testing | Office | 25 | 25 | $27.83 | $696 |
By year: 2022 $110K for 11,007 services; 2023 $92K for 8,649 services; 2024 $87K for 8,222 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shankar Lakhani prescribed most often to Medicare patients was Montelukast Sodium, with 802 prescriptions and refills. In total Shankar Lakhani wrote 3,950 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 802 | 2,157 | 229 | $15K |
| Levocetirizine Dihydrochloride Generic | 696 | 2,035 | 231 | $27K |
| Azelastine Hcl Generic | 324 | 696 | 142 | $14K |
| Fluticasone Propionate Generic | 323 | 728 | 139 | $6,427 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 296 | 544 | 143 | $19K |
| Desloratadine Generic | 285 | 829 | 99 | $29K |
| Ipratropium Bromide Generic | 174 | 412 | 87 | $10K |
| Breo Ellipta Fluticasone/Vilanterol | 131 | 305 | 39 | $117K |
| Triamcinolone Acetonide Generic | 94 | 176 | 56 | $1,037 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 76 | 182 | 29 | $109K |
| Hydroxyzine Hcl Generic | 72 | 133 | 26 | $2,324 |
| Prednisone Generic | 55 | 55 | 46 | $72.85 |
| Ventolin Hfa Albuterol Sulfate | 45 | 67 | 19 | $5,150 |
| Epinephrine Generic | 45 | 53 | 26 | $10K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 42 | 104 | 20 | $10K |
Brand drugs: 651 claims; generic drugs: 3,299 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shankar Lakhani $775 ($775 in general payments such as food, travel and fees) from 10 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $212.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 12 | $212 |
| GlaxoSmithKline, LLC. GSK | 14 | $181 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $99.75 |
| Genzyme Corporation SNY | 4 | $64.73 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $62.3 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $40.82 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $35.6 |
| BioCryst US Sales Co., LLC | 1 | $34.11 |
| CSL Behring CSL.AX | 1 | $23.49 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 1 | $20.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.